Laurus Labs was all set to deliver a bumper year. But currently the stock is down 57% from its all-time high. Let us take a look at some of the reasons for this decline.
The first reason is the reduction in their ARV business. While Laurus is trying to move away from their ARV business as it is a low margin business for the company, they are still very dependent on this segment.
The ARV segment (including API and FDF) contributed to 50% of their revenues in FY22 and about 35% in 9M FY23.
This report by Kotak shows that there has been a major decline in ARV prices for the most recent South African tender. The prices for the Global Fund and PEPFAR move in similar directions as the South African tender.
So even though they were selected as Panel Supplier, it only gives them assured volumes and better pricing.
The second reason is the decline in margins. API has always been a lower margin business for the company and FDF has been the higher margin segment. The company’s strategy was to achieve scale in APIs and forward integrate into manufacturing of FDFs.
This strategy had been working well and helped them increase margins.
However, in this quarter, the company saw a decline in their FDF business and saw a growth in their API business. This effect was more severe in the ARV segment where the company only sold ₹55 Cr worth of ARV formulations in Q2 FY23.
Even in the Non-ARV segment, they saw a decline in FDF revenues and growth in API revenues. So the company’s strategy of increasing FDF sales and decreasing API sales has reversed this quarter which caused a decline in margins.
This also caused an operating deleverage for them as they had done a massive capex into their FDF segment and increased capacity from 5 billion units to 10 billion units. Management had said that this capacity will be fully utilized by the end of Q3 FY23 which did not happen.
They have now said that it will take them until FY24 to fully utilize this capex.
The company also saw a 46% YoY decline in their Onco API business in 9MFY23. Management said that it was because of lower offtake of one key product. Onco API is also a high margin business for the company and a decline in that business reduced margins further.
The other major reason for the fall is their CDMO business. This segment has seen phenomenal growth during the year. But a majority of the revenues from this segment came from the manufacturing of Paxlovid,
which is a covid drug. Since the demand for this drug has reduced greatly, the CDMO vertical, which is their highest margin business, may see a decline in revenues next year.
Their Bio business also did not deliver as expected. The management had said that they are expecting a quarterly run rate of ₹30 Cr from the Bio business and they weren’t able to achieve that due to some productivity issues that they faced during the quarter.
Another issue that the company is facing is increased interest costs. They had undertaken a massive debt-funded capex which was going to be paid down as the capex ramps up.
But this quarter, the management has said that they have no plans of repaying debt even in FY24 and they will start repayment in FY25. Currently, the Net Debt to EBITDA is at 1.3 times, which is not a big concern, but it will increase costs in a rising interest rate environment.
And the last and most important reason for the fall in share price is the guidance miss. The management had guided for $1 billion (~₹7200 Cr) in revenues and 30% EBITDA margin for FY23. But they are going to be missing the guidance.
The valuations for the company were pricing in mother revenue growth and margins in FY23. When they weren’t able to deliver, there was a de-rating in the valuations.
Detailed Thread on Ganesh Green Bharat
#GaneshGreenBharat #IPO
👍Like & Retweet for better reach📢
COMPANY OVERVIEW
• Ganesh green bharat is involved in providing services into multiple verticals catering to :-
(i) Solar System & Allied Services
(ii) Electrical contracting services
(iii) Water Supply Scheme Projects
(iv) Manufacturer of solar photovoltaic (“PV”) modules
• Their core competence lies in bidding for EPC( engineering, procurement & construction) projects & manufacturing of Solar PV Modules with focus on successful delivery of quality products.
Detailed IPO analysis of Gem Enviro
#GemEnviro #IPO
Part 1 (1/2)
👍Like & Retweet for better reach ! 📢
COMPANY OVERVIEW
• Gem Enviro, established in 2013 is into plastic waste management services. They provide various services like Plastic EPR services, collection of plastic waste, ESG & BRSR reporting and sell the recycled products in the market.
A market leader for driver information systems in India?🏍⚡
Detailed Thread on Pricol Ltd🧵
#Pricolltd #pricol
👍Like & Retweet for better reach !
Cmp - ₹394
COMPANY OVERVIEW
• Pricol Ltd manufactures Driver Information & Connected Vehicle Systems (DIS), Controls and actuations and Battery Management Systems. Their legacy products are Display Clusters and Telematics.
• It caters to 2 wheeler, Commercial, Off-road and Passenger Vehicles. It is the world’s 2nd Largest Driver Information System manufacturer for the 2 wheeler segment.
An dominant auto ancillary that into exports for luxury vehicles?
Detailed Thread on RACL Geartech🧵
#RACL #raclgeartech
👍Like & Retweet for better reach !
Cmp - ₹1228
COMPANY OVERVIEW
◦ RACL Geartech Ltd. manufactures transmission gears & Shafts, sub-assembly, precision machined parts and other components for the high end luxury segment.
◦ The company caters mainly to the automotive sector followed by agriculture and industrial sectors.
◦ The company was started as a joint venture between Bharat gears (a Raunaq group enterprise) and PICUP (a U.P Govt. entity) in 1989.
How do you play the theme of a cyclical industry like steel without investing directly in a steel company?🤔
Detailed Thread on RHI Magnesita India Ltd🧵
#RHIMagnesitaIndiaLtd #RHI
👍Like & Retweet for better reach !
Cmp - ₹610
COMPANY OVERVIEW
◦ The company was earlier known as Orient Refractories Ltd post its demerger from Orient Abrasives Ltd in 2010. The company manufactures refractories which find critical applications in various industries and are supplied in both the Indian & Foreign markets.
REFRACTORIES BUSINESS
◦ The company manufactures refractories which find critical applications in industries such as steel, glass, cement and others. The product offerings of the company are as shown:
Do you know about an undervalued monopoly stock in the chemical industry?🧪
Here is a Detailed Thread of Paushak Ltd🧵
👍Like & Retweet for better reach !
Cmp - ₹ 5294
COMPANY OVERVIEW
• The company was incorporated in 1972. They are a part of the Alembic group which is one of the oldest pharmaceutical companies in India. They operate from their plant at Halol in Gujarat.
BUSINESS OVERVIEW
• The company is into the manufacturing and sale of phosgene & phosgene based derivatives. The major product groups for the company are as shown: